Ovarian carcinosarcoma is a rare and aggressive type of ovarian cancer with a poor prognosis and very few treatment options to date. Most patients do not respond well to standard chemotherapy, which makes the search for new therapies urgent. This research investigates if specific enzymes (L-asparaginases), already used in the clinic to treat certain blood cancers, could also be used to treat these rare tumors. If successful, this research could open the door to a completely new and effective treatment strategy for a group of patients that currently has limited hope for survival. As this research offers the possibility of using existing drugs for new diseases, the potential societal impact lies primarily in the fields of public health, pharmaceuticals, and biotechnology. By investigating the feasibility of already existing drugs for new diseases, we can reduce time and cost involved in bringing new treatments to patients. Most importantly, this project contributes to the goal of making innovations in cancer therapy inclusive, by ensuring that even small patient groups with rare tumors are not forgotten.